Buone pratiche per lo sviluppo dei modelli di budget impact a livello regionale
- PMID: 37408853
- PMCID: PMC10318586
- DOI: 10.33393/grhta.2023.2582
Buone pratiche per lo sviluppo dei modelli di budget impact a livello regionale
Abstract
Introduction:: The present work aims to discuss the current scenario of procedures and regulations regarding budget impact analysis/models (BIA/BIM) at regional level in Italy and to provide a standardized approach and detailed recommendations for developing these analyses.
Method:: A systematic review of the literature was conducted in order to collect existing guidelines or specific regional procedures for budget impact analysis in Italy. All the records were analysed in qualitative terms according to a pre-specified analytical framework, based on the ISPOR BIA guidelines. At the end of the analysis, a consensus questionnaire was developed to establish agreed approaches and to provide possible solutions to any critical issues. A list of 39 statements was developed. The survey was distributed to 69 experts who rated their level of agreement with each statement on a 5-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with any given statement.
Results:: Sisty-nine experts answered the questionnaire; a total of 30/39 statements achieved consensus. There was agreement on most of the statements. Time horizon to consider and costs were the issues on which no agreement was found. The results allowed the working group to define a list of good practices.
Conclusion:: While the structure and development of BIM are now well-known and well-applied at national level, there remains a great diversity of management of BIM tools at regional level. Consensus was reached among participating experts, as to the main characteristics, determinants and features of regional BIA/BIM in the perspective of the Italian payer.
Conflict of interest statement
Conflict of interest: The authors declare no potential conflict of interest with respect to the research, authorship and/or publication of this article. The authors declare the following competing interests: Francesco Attanasio,, Alberto Bortolami, Pier Luigi Canonico, Marco Cicoira, Caterina Donati, Fabrizio Gemmi, Andrea Marcellusi, Andrea Marinozzi, Francesco Saverio Mennini, Carolina Moreno, Sara Mucherino, Angela Ragonese, Chiara Roni, Pierluigi Russo, Francesco Russoniello, Claudia Simonelli, Matteo Zanuzzi declare no conflict of interest. Amalia Antenori is an employee and minor shareholder of Eli Lilly, Italy Spa; Matteo Ferrario is an employee of Roche Spa; Ruggero Lasala is member of the Comitato Unico di Ricerca e Formazione at SIFO; Giovanna Scroccaro receives honoraria for lectures;
Figures
References
-
- Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilità e prezzo di un medicinale ai sensi del d.m. 2 agosto 2019. Versione 1.0 - 2020. [(Accessed March; 2023 )]; Online
-
- Ravasio R, Girolomoni G, Gorla R. Analisi di budget impact del biosimilare di etanercept: lo scenario italiano. Glob Reg Health Technol Assess. 2018;5:1–12. doi: 10.33393/grhta.2018.444. - DOI
LinkOut - more resources
Full Text Sources